O-GlcNAc transferase-dependent regulation of RNA Pol II activity in lethal prostate cancer

Description of the granted funding

O-GlcNAc transferase (OGT), a cellular metabolic sensor and responder, is overexpressed in aggressive prostate cancer. We have developed small molecule inhibitors targeting OGT, and these compounds decrease the metabolic activity of prostate cancer cells. According to our research, OGT regulates global gene expression, albeit the mechanistic basis for this is not understood. Recently, we screened thousands of compounds to identify those that sensitize prostate cancer cells to OGT inhibition and identified a promising combination therapy against lethal prostate cancer. In this project, we will: 1) explain the molecular basis on how OGT regulates global gene expression and 2) further develop the promising anti-prostate cancer therapy. In brief, this project will describe a mechanism on how OGT integrates metabolic information to regulate global gene expression in normal and cancer cells, and we also aim to establish novel therapy for prostate cancer.
Show more

Starting year

2020

End year

2024

Granted funding

Harri Itkonen Orcid -palvelun logo
417 656 €

Related funding decisions

335902
Research costs of Academy Research Fellows(2020)
299 993 €

Funder

Research Council of Finland

Funding instrument

Academy research fellows

Other information

Funding decision number

331324

Fields of science

Biochemistry, cell and molecular biology

Research fields

Biokemia, biofysiikka

Identified topics

cancer